IGF-2
An endogenous embryonic growth factor and IGF-1 relative that acts as an autocrine driver of muscle cell differentiation through the IGF-1 receptor.
Insulin-like growth factor 2 (IGF-2) is a naturally occurring peptide growth factor structurally homologous to IGF-1 that plays a central role in embryonic development and remains expressed in adult skeletal muscle, where it functions as an autocrine regulator of myoblast differentiation and myocyte maturation downstream of MyoD activation. It signals through the IGF-1 receptor (PI3K/Akt/mTOR anabolic pathway) and the insulin receptor variant A, while the mannose-6-phosphate/IGF-2 receptor clears bound ligand. IGF-2 has no FDA-approved performance or anabolic applications, and exogenous use is investigational with no human clinical trials establishing safety or efficacy.
Class
Endogenous insulin-like growth factor (single-chain polypeptide)
Half-life
~10-20 minutes
Routes
Subcutaneous, Intramuscular
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Skeletal muscle differentiation
IGF-2 acts as an early autocrine signal induced by the myogenic factor MyoD; its production is essential for myoblast fusion and terminal differentiation into myotubes, establishing it as a key endogenous regulator of muscle development in cell-culture models.
Anabolic signaling via IGF-1R
By binding the IGF-1 receptor, IGF-2 activates the PI3K/Akt/mTOR pathway that drives protein synthesis and cell growth, the same anabolic axis engaged by IGF-1.
Counteracting muscle-wasting signals
Preclinical work shows TGF-beta suppresses muscle differentiation largely by blocking IGF-II autocrine signaling; supplying IGF-II restores muscle protein expression and myotube formation, identifying the pathway as a potential target for muscle-wasting conditions.
Metabolic and glucose effects
Through insulin receptor variant A engagement IGF-2 influences fat metabolism and glucose handling; its insulin-like activity can lower blood glucose, a property observed clinically in tumor-driven IGF-2 hypersecretion.
Tissue development and recovery
As a developmental growth factor expressed in regenerating muscle, IGF-2 is studied in the context of tissue development and recovery under high training load, though evidence remains preclinical.
Mechanism
How it works
IGF-2 is a single-chain polypeptide growth factor structurally homologous to IGF-1 that is central to embryonic and fetal growth and remains expressed in adult skeletal muscle. In muscle it functions as an autocrine regulator: the myogenic transcription factor MyoD induces IGF-2 production, and the secreted peptide then acts back on the same cells to drive myoblast differentiation, fusion, and myocyte maturation.
IGF-2 engages two signaling receptors with opposite consequences. Binding the IGF-1 receptor (IGF-1R) activates the PI3K/Akt/mTOR cascade that mediates anabolic protein synthesis and cell survival, and it also binds insulin receptor variant A (IR-A). In contrast, the mannose-6-phosphate/IGF-2 receptor (M6P/IGF-2R) does not transduce a growth signal but instead internalizes bound IGF-2 for lysosomal degradation, effectively clearing the ligand. The relative abundance of these receptor populations therefore sets the net anabolic output of IGF-2 signaling.
Because IGF-2 shares insulin-like activity, it can act on the insulin receptor to lower blood glucose. Pathological overproduction of IGF-2 by certain tumors causes non-islet cell tumor hypoglycemia, illustrating the peptide's potent metabolic effects and the relevance of the IGF-2:IGF-1 ratio as a signaling readout.
Preclinical evidence positions IGF-2 as a functionally important endogenous anabolic signal in muscle regeneration: autocrine IGF-2 signaling through IGF-1R is required for normal myocyte maturation, and TGF-beta-mediated suppression of this pathway impairs muscle differentiation, which exogenous IGF-I or IGF-II can rescue.
Evidence
Research & clinical studies (7)
An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling
An engineered insulin analog (1Ins) bound both insulin and IGF-1 receptors with roughly 1000-fold stronger IGF-1R binding than native insulin, activating both pathways to give neuroprotective effects and glucose regulation in animal models.
PMID 42139356Proteomics and ex vivo plaque culture identify the insulin-like growth factor axis as a potential regulator of matrix remodelling in carotid plaques
The IGF axis (IGF-1, IGF-2 and binding proteins) was implicated in atherosclerotic plaque stability, with IGF-1 signaling associated with a more stable plaque phenotype showing fewer matrix-degrading enzymes and more structural collagen.
PMID 42001536The IGF signaling axis in thyroid cancer: biological complexity and therapeutic challenges
Dysregulation of the IGF axis, especially an IGF-2/IR-A-dominant autocrine circuit, was linked to thyroid cancer progression, dedifferentiation and radioiodine resistance, with clinical translation limited by signaling redundancy and adaptive resistance.
PMID 42023590Combined Toxicity of Polyamide Microplastics and Fenitrothion Impairs Growth, Intestinal Integrity, and GH-IGF Axis in Nile Tilapia
Combined exposure to polyamide microplastics and fenitrothion downregulated igf-2 gene expression and impaired growth in Nile tilapia, with coexposure effects on the GH-IGF axis exceeding those of either contaminant alone.
PMID 42033174TGF-beta inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II
In mouse and human primary myoblast cultures, TGF-beta inhibited muscle differentiation mainly by suppressing IGF-II autocrine signaling, and exogenous IGF-I or IGF-II restored muscle protein expression and myotube formation.
PMID 21106882Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation
IGF-II was identified as an early MyoD-induced autocrine signal essential for myocyte fusion and terminal differentiation into myotubes, marking it as a key endogenous regulator of skeletal muscle development.
PMID 12941952IGF-2-mediated hypoglycemia in a patient with a phyllodes tumor of the breast: a rare presentation of non-islet cell tumor hypoglycemia
A breast phyllodes tumor secreting IGF-2 caused non-islet cell tumor hypoglycemia, diagnosed by an elevated IGF-2:IGF-1 ratio and fully resolved after surgical resection.
PMID 42214434Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer
- Hypoglycemia risk
- Acromegaly
IGF-2 carries a moderate risk profile in research contexts. Because it can promote growth signaling and lower blood glucose, it is a concern in the setting of active or predisposing cancer and in states of glucose instability. No human safety data exist for exogenous use; consult a qualified professional before any decision.
FAQ
IGF-2 — common questions
What is IGF-2?
IGF-2 (insulin-like growth factor 2, IGF-II) is a naturally occurring peptide growth factor structurally homologous to IGF-1. It is central to embryonic development and remains expressed in adult skeletal muscle, where it acts as an autocrine regulator of myoblast differentiation and myocyte maturation downstream of MyoD.
How does IGF-2 differ from IGF-1?
The two are structurally homologous and both activate the IGF-1 receptor and PI3K/Akt anabolic signaling, but IGF-2 has a distinct receptor-binding profile. It also engages insulin receptor variant A and the M6P/IGF-2 receptor, the latter of which clears the ligand by lysosomal degradation rather than transmitting a growth signal.
What is IGF-2 primarily studied for?
Research interest centers on muscle growth, fat metabolism, tissue development, and recovery, largely through its role as an autocrine driver of skeletal muscle cell differentiation.
What are the reported benefits of IGF-2?
Preclinical and cell-biology literature documents effects on muscle differentiation and anabolic signaling, counteracting TGF-beta-driven muscle-wasting signals, and metabolic/glucose effects. Individual response varies and effects depend on context; no human efficacy has been established.
What are the side effects and contraindications of IGF-2?
Reported considerations include active cancer, hypoglycemia risk, and acromegaly. Its insulin-like activity can lower blood glucose, and its growth-promoting signaling is a concern in cancer-predisposing states.
Is IGF-2 approved or legal to use?
IGF-2 is an endogenous growth factor with no FDA-approved exogenous drug product and no NDA or IND as a primary active ingredient. It is research-use only, and no human clinical trials have established safety or efficacy for performance or anabolic uses.
How is IGF-2 administered in research?
Reported research routes are subcutaneous and intramuscular. The circulating half-life is short, on the order of 10-20 minutes.
